April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Oral Synthetic cis-Retinoid Therapy in Subjects with Leber Congenital Amaurosis (LCA) due to Lecithin: Retinol Acyltransferase (LRAT) or Retinal Pigment Epithelial 65 Protein (RPE65) mutations: Preliminary Results of a Phase Ib Open Label Trial
Author Affiliations & Notes
  • Robert K. Koenekoop
    McGill Ocular Genetics Laboratory, McGill University Health Centre, Montreal, Quebec, Canada
  • Julie Racine
    McGill Ocular Genetics Laboratory, McGill University Health Centre, Montreal, Quebec, Canada
  • Sulaiman Al Humaid
    McGill Ocular Genetics Laboratory, McGill University Health Centre, Montreal, Quebec, Canada
  • Ruifang Sui
    Ophthalmology, Peking Union Medical College Hospital, Beijing, China
  • Elias Traboulsi
    Cleveland Clinic, Cole Eye Institute, Cleveland, Ohio
  • Julianna Sallum
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Dipak Panigrahi
    Therapeutics, QLT Inc, Vancouver, British Columbia, Canada
  • Kris Palczewski
    Pharmacology, Case Western Reserve University, Cleveland, Ohio
  • David Saperstein
    Vitreoretinal Associates of Washington, Seattle, Washington
  • Footnotes
    Commercial Relationships  Robert K. Koenekoop, QLT Inc. (F); Julie Racine, None; Sulaiman Al Humaid, None; Ruifang Sui, None; Elias Traboulsi, None; Julianna Sallum, None; Dipak Panigrahi, QLT Inc (E); Kris Palczewski, QLT Inc (P); David Saperstein, QLT Inc (P)
  • Footnotes
    Support  CIHR, FFB-C, QLT Inc., Heidelberg, NIH, Reseau Vision, and FRSQ
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3323. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Robert K. Koenekoop, Julie Racine, Sulaiman Al Humaid, Ruifang Sui, Elias Traboulsi, Julianna Sallum, Dipak Panigrahi, Kris Palczewski, David Saperstein; Oral Synthetic cis-Retinoid Therapy in Subjects with Leber Congenital Amaurosis (LCA) due to Lecithin: Retinol Acyltransferase (LRAT) or Retinal Pigment Epithelial 65 Protein (RPE65) mutations: Preliminary Results of a Phase Ib Open Label Trial. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3323.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess safety and efficacy of an oral synthetic cis-retinoid prodrug (QLT091001) in subjects with LCA due to mutations in the Lecithin:Retinol Acyltransferase (LRAT) or Retinal Pigment Epithelial 65 Protein (RPE65) genes. There are no proven therapies for this progressive retinal degeneration. QLT091001 has been shown to restore vision in mouse and dog models with LCA.

Methods: : In this ongoing, IRB approved, proof-of-concept clinical trial, subjects with LCA are treated daily for 7 days with oral QLT091001 at the Montreal Children's Hospital. Visual function testing, ophthalmic and physical examinations, electrocardiograms and laboratory tests are completed before and after treatment at predetermined time points.

Results: : Nine of 12 planned subjects with LCA due to LRAT or RPE65 mutations have been enrolled. Preliminary results show improvements in Early Treatment of Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) and Goldmann visual fields (GVF). In some cases, BCVA and GVF improvements have persisted for up to 11 months beyond the end of treatment. Many subjects reported meaningful improvements in their activities of daily living (ADLs). There were no serious adverse events. Transient headache and photophobia were reported and reversible elevations in triglyceride levels and reduction in HDL were recorded.

Conclusions: : In this study, seven days of oral QLT091001 was generally well-tolerated and led to rapid and sustained vision improvements, as well as subjective improvements in ADLs. Adverse events were transient and/or reversible. We have identified a population of dormant photoreceptors that rapidly respond to external manipulation. We are currently enrolling the remainder of the LCA subjects and expect to report on the full study results upon study completion.

Clinical Trial: : http://www.clinicaltrials.gov NCT01014052

Keywords: retinal degenerations: hereditary • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • photoreceptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×